PET/MRI在前列腺癌中的应用:系统综述与荟萃分析
PET/MRI对原发肿瘤基于患者的汇总灵敏度为94.9%,再分期汇总检出率为80.9%,且放射性标记PSMA示踪剂检出率高于胆碱(81.8%对77.3%)。结论认为PET/MRI对原发前列腺癌检测高度敏感,对复发疾病检出率高,尤其使用放射性标记PSMA时。
要点
- PET/MRI对原发前列腺癌基于患者的汇总灵敏度达94.9%。
- 再分期汇总检出率为80.9%,PSMA示踪剂高于胆碱(81.8%对77.3%)。
- 放射性标记PSMA是纳入研究中最常用的示踪剂。
核心结论
- PET/MRI对原发前列腺癌检测高度敏感,对复发疾病检出率高,尤其使用放射性标记PSMA时。
主要发现
- 原发肿瘤基于患者的汇总灵敏度为94.9%。
- 再分期汇总检出率为80.9%,放射性标记PSMA为81.8%,胆碱为77.3%。
- 24项研究中初始疾病分期是PET/MRI的主要适应证,放射性标记PSMA是最常用的示踪剂。
关键数值与推荐
- 纳入标准要求考虑混合PET/MRI、样本量≥10例患者且原始数据足以完成2×2列联表。
临床怎么用
- PET/MRI可用于前列腺癌原发肿瘤检测与再分期评估,优先选择放射性标记PSMA示踪剂可能提高复发检出率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: In recent years, the clinical availability of scanners for integrated positron emission tomography (PET) and magnetic resonance imaging (MRI) has enabled the practical potential of multimodal, combined metabolic-receptor, anatomical, and functional imaging to be explored. The present systematic review and meta-analysis summarize the diagnostic information provided by PET/MRI in patients with prostate cancer (PCa). MATERIALS AND METHODS: A literature search was conducted in three different databases. The terms used were "choline" or "prostate-specific membrane antigen - PSMA" AND "prostate cancer" or "prostate" AND "PET/MRI" or "PET MRI" or "PET-MRI" or "positron emission tomography/magnetic resonance imaging." All relevant records identified were combined, and the full texts were retrieved. Reports were excluded if (1) they did not consider hybrid PET/MRI; or (2) the sample size was < 10 patients; or (3) the raw data were not enough to enable the completion of a 2 × 2 contingency table. RESULTS: Fifty articles were eligible for systematic review, and 23 for meta-analysis. The pooled data concerned 2104 patients. Initial disease staging was the main indication for PET/MRI in 24 studies. Radiolabeled PSMA was the tracer most frequently used. In primary tumors, the pooled sensitivity for the patient-based analysis was 94.9%. At restaging, the pooled detection rate was 80.9% and was higher for radiolabeled PSMA than for choline (81.8% and 77.3%, respectively). CONCLUSIONS: PET/MRI proved highly sensitive in detecting primary PCa, with a high detection rate for recurrent disease, particularly when radiolabeled PSMA was used.
引用
- Evangelista L, Zattoni F, Cassarino G, et al. PET/MRI in prostate cancer: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2020. PMID: 32901351. doi:10.1007/s00259-020-05025-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。